SCHEMBL3523456

SCHEMBL3523456

O=C([CH]OC(F)(F)F)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CES1 P23141 3/20 0.47
AKT1 P31749 2/20 0.47
NFE2L2 Q16236 1/20 0.45
MAOB P27338 2/20 0.45
CYP1B1 Q16678 2/20 0.45
CYP1A1 P04798 1/20 0.45
CES2 O00748 2/20 0.43
LMNA P02545 3/20 0.42
RECQL P46063 2/20 0.42
PLIN1 O60240 2/20 0.42
MAPT P10636 2/20 0.42
PLIN5 Q00G26 2/20 0.42
ABHD5 Q8WTS1 2/20 0.42
BCHE P06276 1/20 0.42
TNFRSF1A P19438 1/20 0.42
ACHE P22303 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649015 0.73 AKR1C1 (0.48) ALDH1A1CES1CES2LMNAMAPT
SCHEMBL8438487 0.72 ALDH1A1 (0.54) ALDH1A1MAPK1TDP1CES1AKT1
SCHEMBL874660 0.72 ALDH1A1 (0.54) ALDH1A1MAPK1TDP1CES1AKT1
SCHEMBL7149428 0.71 CES1 (0.41) ALDH1A1MAPK1TDP1CES1CES2
SCHEMBL23978379 0.69 NFE2L2 (0.57) ALDH1A1MAPK1TDP1CES1AKT1
SCHEMBL12900918 0.69 NFE2L2 (0.57) ALDH1A1MAPK1TDP1CES1AKT1
SCHEMBL6722688 0.69 CES1 (0.43) ALDH1A1MAPK1TDP1CES1MAOB
SCHEMBL11505486 0.69 ALDH1A1 (0.50) ALDH1A1MAPK1TDP1CES1AKT1
SCHEMBL7361299 0.69 NFE2L2 (0.57) ALDH1A1MAPK1TDP1CES1AKT1
SCHEMBL7361301 0.69 NFE2L2 (0.57) ALDH1A1MAPK1TDP1CES1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709468-B2 Imidazo based heterocycles ABBOTT LABORATORIES (US) 2010-05-04 US disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 CN disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-20070099925-A1 Novel imidazo based heterocycles ABBVIE INC. 2007-05-03 US disclosed
CN-1878777-A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2006-12-13 CN disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099925-A1 Novel imidazo based heterocycles CDK4, CDK2, MAP3K19 ALDH1A1 1071/4885MAPK1 52/4885TDP1 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.